- Home
- HKPD vs KALA Comparison
HKPD vs KALA Comparison
Compare HKPD & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKPD
- KALA
- Stock Information
- Founded
- HKPD 2016
- KALA 2009
- Country
- HKPD Hong Kong
- KALA United States
- Employees
- HKPD N/A
- KALA N/A
- Industry
- HKPD Other Pharmaceuticals
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- HKPD Health Care
- KALA Health Care
- Exchange
- HKPD Nasdaq
- KALA Nasdaq
- Market Cap
- HKPD 30.3M
- KALA 27.3M
- IPO Year
- HKPD 2025
- KALA 2017
- Fundamental
- Price
- HKPD N/A
- KALA $7.69
- Analyst Decision
- HKPD
- KALA Strong Buy
- Analyst Count
- HKPD 0
- KALA 2
- Target Price
- HKPD N/A
- KALA $15.00
- AVG Volume (30 Days)
- HKPD 555.0K
- KALA 47.7K
- Earning Date
- HKPD 01-01-0001
- KALA 11-12-2024
- Dividend Yield
- HKPD N/A
- KALA N/A
- EPS Growth
- HKPD N/A
- KALA N/A
- EPS
- HKPD 0.18
- KALA N/A
- Revenue
- HKPD $16,688,364.00
- KALA N/A
- Revenue This Year
- HKPD N/A
- KALA N/A
- Revenue Next Year
- HKPD N/A
- KALA N/A
- P/E Ratio
- HKPD $14.87
- KALA N/A
- Revenue Growth
- HKPD 32.91
- KALA N/A
- 52 Week Low
- HKPD $2.40
- KALA $4.21
- 52 Week High
- HKPD $3.79
- KALA $8.79
- Technical
- Relative Strength Index (RSI)
- HKPD N/A
- KALA 61.18
- Support Level
- HKPD N/A
- KALA $7.00
- Resistance Level
- HKPD N/A
- KALA $7.85
- Average True Range (ATR)
- HKPD 0.00
- KALA 0.58
- MACD
- HKPD 0.00
- KALA 0.05
- Stochastic Oscillator
- HKPD 0.00
- KALA 51.97
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.